A greater understanding of the biology of mesothelioma has led to new clinical trials testing immunotherapies and targeted drugs against the disease.
Cancer Research UK and Biotecnol Limited will trial an experimental immuno-oncology treatment for some patients with advanced tumours.
An exciting new partnership will see a combination of drugs tested in mesothelioma, lung and pancreatic cancers for the first time.
Suppressing the body's natural defences could improve how well mesothelioma patients respond to certain treatments, a US study suggests.
One in 17 British carpenters born in the 1940s will die of mesothelioma - a cancer of the lining of the lung caused by asbestos - according to new research* published in...